
Opinion|Videos|March 25, 2025
Pharmacist-Led Strategies for Adverse Event Management in mCRC
Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In what ways do pharmacists contribute to managing adverse events and toxicity for patients undergoing mCRC treatment?
- What factors influence patient adherence to third-line therapies for mCRC, and how can pharmacists improve patient education to address these challenges and ensure better adherence to treatment regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure
2
Fuzuloparib Monotherapy Improves PFS in Advanced Ovarian Cancer, but Adding Apatinib Offers No Additional Benefit
3
Top 5 Inflammation Articles of 2025
4
House Republicans Block Vote on ACA Subsidy Extension
5







































